CoChat
Sign Up
Cited by 50

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing

Nguyen, Lien D., Wei, Zhiyun, Silva, M. Catarina, Barberán-Soler, Sergio, Zhang, Jiarui, Rabinovsky, Rosalia, Muratore, Christina R., Stricker, Jonathan M. S., Hortman, Colin, Young-Pearse, Tracy L., Haggarty, Stephen J., Krichevsky, Anna M.·2023·Nature Communications
DOI 10.1038/s41467-023-43293-0PMC PMC10663445

Published version of a preprint

Open this paper in CoChat — free account

Abstract

MicroRNAs (miRNAs) regulate fundamental biological processes by silencing mRNA targets and are dysregulated in many diseases. Therefore, miRNA replacement or inhibition can be harnessed as potential therapeutics. However, existing strategies for miRNA modulation using oligonucleotides and gene therapies are challenging, especially for neurological diseases, and none have yet gained clinical approval. We explore a different approach by screening a biodiverse library of small molecule compounds for their ability to modulate hundreds of miRNAs in human induced pluripotent stem cell-derived neurons. We demonstrate the utility of the screen by identifying cardiac glycosides as potent inducers of miR-132, a key neuroprotective miRNA downregulated in Alzheimer’s disease and other tauopathies. Coordinately, cardiac glycosides downregulate known miR-132 targets, including Tau, and protect rodent and human neurons against various toxic insults. More generally, our dataset of 1370 drug-like compounds and their effects on the miRNome provides a valuable resource for further miRNA-based drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-43293-0

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Experimental workflow and overview of screen results in NGN2-iNs. a NGN2-iN generation, compound treatment, and miRNA-seq workflow (N = 1 per compound, 1902 compounds in total, created with BioRender.com). b Average number of miRNA species detected per sample by miRNA-seq at various count cut-offs (N = 1371 samples). Error bars represent mean +/− SD. c Expression levels of the 100 most abundant miRNAs in vehicle-treated samples. miR-26a-5p was the most abundant miRNA detected, miR-132-3p was the 27th (N = 42 DMSO-treated samples). Error bars represent mean +/− SEM. d Shared miRNAs with the lowest coefficient of variation in the plates tested. e Waterfall plot for miR-132 expression in plate 2 was shown in blue. Samples treated with ouabain, digoxin, and the positive control forskolin showed the highest level of miR-132. miR-107, miR-103a-3p, and miR-191-5p were shown in red, green, and purple, respectively.
Fig. 1 Experimental workflow and overview of screen results in NGN2-iNs. a NGN2-iN generation, compound treatment, and miRNA-seq workflow (N = 1 per compound, 1902 compounds in total, created with BioRender.com). b Average number of miRNA species detected per sample by miRNA-seq at various count cut-offs (N = 1371 samples). Error bars represent mean +/− SD. c Expression levels of the 100 most abundant miRNAs in vehicle-treated samples. miR-26a-5p was the most abundant miRNA detected, miR-132-3p was the 27th (N = 42 DMSO-treated samples). Error bars represent mean +/− SEM. d Shared miRNAs with the lowest coefficient of variation in the plates tested. e Waterfall plot for miR-132 expression in plate 2 was shown in blue. Samples treated with ouabain, digoxin, and the positive control forskolin showed the highest level of miR-132. miR-107, miR-103a-3p, and miR-191-5p were shown in red, green, and purple, respectively.CC BY · PubMed Central
Fig. 2 Landscape of compound effects on miRNome in NGN2-iNs. a Top small molecule hits for miRNAs with neurologic relevance. b UMAP analysis of miRNomes affected by compounds (N = 1437 samples). c Clustered heatmap illustrating small molecule compounds (CC1-CC5) as modulators of miRNAs (MC1-MC4). Heatmaps showing miRNAs regulated by compounds related to cytoskeletal signaling (N = 42 vs 36) (d), neuronal signaling (N = 42 vs 204) (e), protein tyrosine kinase (N = 42 vs 67) (f), and DNA damage (N = 42 vs 80) (g), respectively (p < 0.001, t-test). Representative miRNAs affected by compounds predicted to cross the BBB (N = 948 vs 447) (h), involved in CNS system (N = 1145 vs 250) (i), and kinase inhibitors (N = 1062 vs 333) (j). p = 0.0004, 9.8E−5, and 0.0021, respectively; two-sided t-test without assumption of equal SD. k Compounds simultaneously upregulating multiple "neuroprotective" and downregulating “neurotoxic” miRNAs. l miRNAs showing the strongest positive and negative correlations with miR-132 in all sequenced samples. **p < 0.01; ***p < 0.001, unpaired two-tailed Student’s t test; CC compound cluster, MC miRNA cluster, AD Alzheimer’s disease, HD Huntington’s disease, PD Parkinson’s Disease, SP synaptic plasticity, BBB blood-brain barrier.
Fig. 2 Landscape of compound effects on miRNome in NGN2-iNs. a Top small molecule hits for miRNAs with neurologic relevance. b UMAP analysis of miRNomes affected by compounds (N = 1437 samples). c Clustered heatmap illustrating small molecule compounds (CC1-CC5) as modulators of miRNAs (MC1-MC4). Heatmaps showing miRNAs regulated by compounds related to cytoskeletal signaling (N = 42 vs 36) (d), neuronal signaling (N = 42 vs 204) (e), protein tyrosine kinase (N = 42 vs 67) (f), and DNA damage (N = 42 vs 80) (g), respectively (p < 0.001, t-test). Representative miRNAs affected by compounds predicted to cross the BBB (N = 948 vs 447) (h), involved in CNS system (N = 1145 vs 250) (i), and kinase inhibitors (N = 1062 vs 333) (j). p = 0.0004, 9.8E−5, and 0.0021, respectively; two-sided t-test without assumption of equal SD. k Compounds simultaneously upregulating multiple "neuroprotective" and downregulating “neurotoxic” miRNAs. l miRNAs showing the strongest positive and negative correlations with miR-132 in all sequenced samples. **p < 0.01; ***p < 0.001, unpaired two-tailed Student’s t test; CC compound cluster, MC miRNA cluster, AD Alzheimer’s disease, HD Huntington’s disease, PD Parkinson’s Disease, SP synaptic plasticity, BBB blood-brain barrier.CC BY · PubMed Central
Fig. 3 Validation of top miR-132-upregulating candidate compounds in primary rat cortical neurons and human NGN2-iNs. a Top compounds that showed significant upregulation of miR-132 in primary rat cortical neurons and human NGN2-iNs after 24 h treatment (RT-qPCR analysis, unpaired two-tailed Student’s t test compared to DMSO controls, N = 8 biological replicates for DMSO and forskolin, N = 4 for others). b Dose curve experiments were performed in DIV14 rat primary neurons after 24 h treatment. Solid lines were used for cardiac glycosides, and dotted lines were used for other compounds. EC50 and max fold change were calculated using sigmoidal fit, 4 parameters. (N = 3–8 biological replicates). c Cardiac glycosides, forskolin, and BIX02188 upregulated the primary transcript of miR-132 24 h after treatment in rat primary neurons (unpaired two-tailed Student’s t test compared to DMSO control, N = 4 biological replicates). d, e Upregulation of miR-132 in rat primary neurons was completely blocked by pretreatment with CREB inhibitor (N = 3 biological replicates) or actinomycin D (N = 4 biological replicates, one-way ANOVA, followed by Dunnett’s multiple comparisons test comparing to DMSO/DMSO control). f Knocking-down ATP1A1 or ATP1A3, the predominant isoforms in neurons, upregulated pri-miR-132 and mature miR-132 in rat primary neurons (unpaired two-tailed Student’s t test compared to DMSO control, N = 3-4 biological replicates for ATP1A1 KD, N = 6 for ATP1A3 KD). All error bars represent mean +/− SD. Source data are provided as a Source Data file.
Fig. 3 Validation of top miR-132-upregulating candidate compounds in primary rat cortical neurons and human NGN2-iNs. a Top compounds that showed significant upregulation of miR-132 in primary rat cortical neurons and human NGN2-iNs after 24 h treatment (RT-qPCR analysis, unpaired two-tailed Student’s t test compared to DMSO controls, N = 8 biological replicates for DMSO and forskolin, N = 4 for others). b Dose curve experiments were performed in DIV14 rat primary neurons after 24 h treatment. Solid lines were used for cardiac glycosides, and dotted lines were used for other compounds. EC50 and max fold change were calculated using sigmoidal fit, 4 parameters. (N = 3–8 biological replicates). c Cardiac glycosides, forskolin, and BIX02188 upregulated the primary transcript of miR-132 24 h after treatment in rat primary neurons (unpaired two-tailed Student’s t test compared to DMSO control, N = 4 biological replicates). d, e Upregulation of miR-132 in rat primary neurons was completely blocked by pretreatment with CREB inhibitor (N = 3 biological replicates) or actinomycin D (N = 4 biological replicates, one-way ANOVA, followed by Dunnett’s multiple comparisons test comparing to DMSO/DMSO control). f Knocking-down ATP1A1 or ATP1A3, the predominant isoforms in neurons, upregulated pri-miR-132 and mature miR-132 in rat primary neurons (unpaired two-tailed Student’s t test compared to DMSO control, N = 3-4 biological replicates for ATP1A1 KD, N = 6 for ATP1A3 KD). All error bars represent mean +/− SD. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Cardiac glycosides upregulate miR-132 to downregulate miR-132 targets and provide neuroprotection in primary rat cortical neurons. a–c 100 nM oleandrin upregulated pri- and mature miR-132/212 and downregulated their mRNA targets over time (RT-qPCR analysis, N ~ 6 biological replicates, unpaired two-tailed t-test comparing to 0 h, adjusted for multiple comparisons). d–h Oleandrin downregulated total Tau (N = 13 biological replicates), pTau (AT8, N = 13, and S396, N = 7), and FOXO3a (N = 12) protein after 72 h treatment (Western blot analysis, unpaired two-tailed Student’s t test). i–k Less mature neurons were more susceptible to cardiac glycoside toxicity, whereas more mature neurons were resistant. Primary rat neurons were treated with various doses of digoxin, oleandrin, and proscillaridin A for 96 h before viability was measured using WST-1. Cells treated at DIV7 showed a dose-dependent reduction in viability. In contrast, cells treated at DIV14, 21, or 28 showed little loss of viability, particularly at EC100 for miR-132 upregulation (unpaired t-test comparing to DMSO, adjusted for multiple comparisons, N = 4–10 biological replicates per dose). l For DIV7 neurons, proscillaridin A was mildly toxic at baseline. However, both proscillaridin A and oleandrin fully rescued viability loss due to glutamate treatment (2-way ANOVA, followed by Dunnet’s multiple comparisons test, N ~ 16 biological replicates per condition). m, n For DIV21 neurons, proscillaridin A and oleandrin were not toxic at baseline and rescued viability loss due to glutamate or Aβ oligomer treatment (2-way ANOVA, followed by Dunnet’s multiple comparisons test, N ~ 16 biological replicates per condition). o Pre-transfection with miR-132 and -212 inhibitors partially reduced the rescue of viability provided by proscillaridin A and oleandrin (2-way ANOVA, followed by Tukey’s multiple comparisons test, N ~ 15 biological replicates per condition). All error bars represent mean +/− SD. Source data are provided as a Source Data file.
Fig. 4 Cardiac glycosides upregulate miR-132 to downregulate miR-132 targets and provide neuroprotection in primary rat cortical neurons. a–c 100 nM oleandrin upregulated pri- and mature miR-132/212 and downregulated their mRNA targets over time (RT-qPCR analysis, N ~ 6 biological replicates, unpaired two-tailed t-test comparing to 0 h, adjusted for multiple comparisons). d–h Oleandrin downregulated total Tau (N = 13 biological replicates), pTau (AT8, N = 13, and S396, N = 7), and FOXO3a (N = 12) protein after 72 h treatment (Western blot analysis, unpaired two-tailed Student’s t test). i–k Less mature neurons were more susceptible to cardiac glycoside toxicity, whereas more mature neurons were resistant. Primary rat neurons were treated with various doses of digoxin, oleandrin, and proscillaridin A for 96 h before viability was measured using WST-1. Cells treated at DIV7 showed a dose-dependent reduction in viability. In contrast, cells treated at DIV14, 21, or 28 showed little loss of viability, particularly at EC100 for miR-132 upregulation (unpaired t-test comparing to DMSO, adjusted for multiple comparisons, N = 4–10 biological replicates per dose). l For DIV7 neurons, proscillaridin A was mildly toxic at baseline. However, both proscillaridin A and oleandrin fully rescued viability loss due to glutamate treatment (2-way ANOVA, followed by Dunnet’s multiple comparisons test, N ~ 16 biological replicates per condition). m, n For DIV21 neurons, proscillaridin A and oleandrin were not toxic at baseline and rescued viability loss due to glutamate or Aβ oligomer treatment (2-way ANOVA, followed by Dunnet’s multiple comparisons test, N ~ 16 biological replicates per condition). o Pre-transfection with miR-132 and -212 inhibitors partially reduced the rescue of viability provided by proscillaridin A and oleandrin (2-way ANOVA, followed by Tukey’s multiple comparisons test, N ~ 15 biological replicates per condition). All error bars represent mean +/− SD. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Cardiac glycosides upregulate miR-132 to downregulate miR-132 targets and provide neuroprotection in primary rat cortical neurons. WT and P301L neurons were differentiated for 6 weeks, then treated with cardiac glycosides for 24 h or 72 h. a Representative Western blot for WT neurons treated with proscillaridin A (ProsA). A dose-dependent reduction in total Tau and p-Tau S396 was observed at both 24 h and 72 h. The dotted lines indicated that separate Western blots were put together. Similar results were obtained independently 3 times. b, c In parallel, a reduction in MAPT mRNA and an increase in pri-miR-132 and miR-132 RNA were observed (N = 1 biological sample). Similar results were also observed in Tau P301L neurons by Western blot (d) and mRNA (e, f) analysis. g–r Western blot densitometry quantification of dose-dependent effects on Tau (TAU5), pTau S396 and the synaptic makers PSD95, SYN1, and β-III-Tubulin (N = 3 biological replicates) in WT and P301L neurons treated for 24 h or 72 h. The yellow shades indicate compound concentrations leading to <30% loss of at least two synaptic/microtubule markers. All error bars represent mean +/− SEM. Source data are provided as a Source Data file.
Fig. 5 Cardiac glycosides upregulate miR-132 to downregulate miR-132 targets and provide neuroprotection in primary rat cortical neurons. WT and P301L neurons were differentiated for 6 weeks, then treated with cardiac glycosides for 24 h or 72 h. a Representative Western blot for WT neurons treated with proscillaridin A (ProsA). A dose-dependent reduction in total Tau and p-Tau S396 was observed at both 24 h and 72 h. The dotted lines indicated that separate Western blots were put together. Similar results were obtained independently 3 times. b, c In parallel, a reduction in MAPT mRNA and an increase in pri-miR-132 and miR-132 RNA were observed (N = 1 biological sample). Similar results were also observed in Tau P301L neurons by Western blot (d) and mRNA (e, f) analysis. g–r Western blot densitometry quantification of dose-dependent effects on Tau (TAU5), pTau S396 and the synaptic makers PSD95, SYN1, and β-III-Tubulin (N = 3 biological replicates) in WT and P301L neurons treated for 24 h or 72 h. The yellow shades indicate compound concentrations leading to <30% loss of at least two synaptic/microtubule markers. All error bars represent mean +/− SEM. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Cardiac glycosides protect human Tau P301L iPSC-neurons from diverse toxic insults. Compounds concentration effect on neuronal viability after 24 h or 72 h treatment of WT (a–c) and Tau P301L (d–f) human neurons (Data points indicate mean ± SD; N = 6 biological replicates; unpaired two-tailed Student’s t test). g Schematic of the assay used to measure neuroprotective effects by cardiac glycosides in tauopathy neurons. h–j Cardiac glycosides rescued the loss of viability in P301L neurons due to NMDA, rotenone, or Aβ42 oligomer treatment (N = 4 biological replicates, unpaired two-tailed Student’s t test). All error bars represent mean +/− SEM. k Representative images for P301L neurons at 8 weeks of differentiation treated with cardiac glycosides and each stressor compound. Total Tau (K9JA antibody) staining is shown in red, and MAP2 in green. Similar results were obtained independently 2 times. Scale bars are 200 μm. Source data are provided as a Source Data file.
Fig. 6 Cardiac glycosides protect human Tau P301L iPSC-neurons from diverse toxic insults. Compounds concentration effect on neuronal viability after 24 h or 72 h treatment of WT (a–c) and Tau P301L (d–f) human neurons (Data points indicate mean ± SD; N = 6 biological replicates; unpaired two-tailed Student’s t test). g Schematic of the assay used to measure neuroprotective effects by cardiac glycosides in tauopathy neurons. h–j Cardiac glycosides rescued the loss of viability in P301L neurons due to NMDA, rotenone, or Aβ42 oligomer treatment (N = 4 biological replicates, unpaired two-tailed Student’s t test). All error bars represent mean +/− SEM. k Representative images for P301L neurons at 8 weeks of differentiation treated with cardiac glycosides and each stressor compound. Total Tau (K9JA antibody) staining is shown in red, and MAP2 in green. Similar results were obtained independently 2 times. Scale bars are 200 μm. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Transcriptome analysis of human iPSC-neurons treated with cardiac glycosides. a Workflow of the experiment design (created with BioRender.com). b Principal component analysis (PCA) indicated the strong and dose-dependent alteration of global transcriptomic profiles after treatments. c Volcano plots showed significant down- and upregulated genes, labeled in blue and red dots, respectively. All dosages were grouped to be compared with DMSO (N = 3 vs 3). Stars highlighted dysregulated genes involved in neuronal activity and health. Wald test with FDR correction analyzed using DESeq2. d Venn diagram indicated the similarity of pathways affected by three cardiac glycosides. e Selected neuronal pathways enriched for the down-regulated genes. f Selected transcription- and response-related pathways enriched for the upregulated genes. g Effects of cardiac glycosides on the expression of transcription factors (TFs) that have binding sites on MIR132 promoter. h Working model showing the effects of cardiac glycosides: cardiac glycosides act through their conventional mechanism leading to the transcriptional upregulation of miR-132. The increase in miR-132, together with other pathways altered by cardiac glycosides, downregulated various forms of Tau and provided neuroprotection against toxic insults (created with BioRender.com).
Fig. 7 Transcriptome analysis of human iPSC-neurons treated with cardiac glycosides. a Workflow of the experiment design (created with BioRender.com). b Principal component analysis (PCA) indicated the strong and dose-dependent alteration of global transcriptomic profiles after treatments. c Volcano plots showed significant down- and upregulated genes, labeled in blue and red dots, respectively. All dosages were grouped to be compared with DMSO (N = 3 vs 3). Stars highlighted dysregulated genes involved in neuronal activity and health. Wald test with FDR correction analyzed using DESeq2. d Venn diagram indicated the similarity of pathways affected by three cardiac glycosides. e Selected neuronal pathways enriched for the down-regulated genes. f Selected transcription- and response-related pathways enriched for the upregulated genes. g Effects of cardiac glycosides on the expression of transcription factors (TFs) that have binding sites on MIR132 promoter. h Working model showing the effects of cardiac glycosides: cardiac glycosides act through their conventional mechanism leading to the transcriptional upregulation of miR-132. The increase in miR-132, together with other pathways altered by cardiac glycosides, downregulated various forms of Tau and provided neuroprotection against toxic insults (created with BioRender.com).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 74

  1. Wang, F., Zuroske, T. & Watts, J. K. RNA therapeutics on the rise. Nat. Rev. Drug Discov. 19, 441–442 (2020). · DOI
  2. Warner, K. D., Hajdin, C. E. & Weeks, K. M. Principles for targeting RNA with drug-like small molecules. Nat. Rev. Drug Discov. 17, 547–558 (2018). · DOI
  3. Gebert, L. F. R. & MacRae, I. J. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20, 21–37 (2019). · DOI · Paper page
  4. Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172–1187 (2012). · DOI · Paper page
  5. Chen, Y., Gao, D. Y. & Huang, L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv. Drug Deliv. Rev. 81, 128–141 (2015). · DOI
  6. Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–789 (2010). · DOI
  7. Watts, J. K., Brown, R. H. & Khvorova, A. Nucleic acid therapeutics for neurological diseases. Neurotherapeutics 16, 245–247 (2019). · DOI
  8. Nguyen, L. D., Chau, R. K. & Krichevsky, A. M. Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer’s disease and related dementias. Genes 12, 2005 (2021). · DOI
  9. Gumireddy, K. et al. Small-molecule inhibitors of microrna miR-21 function. Angew. Chem. Int. Ed. Engl. 47, 7482–7484 (2008). · DOI
  10. Young, D. D., Connelly, C. M., Grohmann, C. & Deiters, A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 132, 7976–7981 (2010). · DOI
  11. Velagapudi, S. P., Gallo, S. M. & Disney, M. D. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat. Chem. Biol. 10, 291–297 (2014). · DOI
  12. Connelly, C. M., Boer, R. E., Moon, M. H., Gareiss, P. & Schneekloth, J. S. Jr Discovery of inhibitors of microRNA-21 processing using small molecule microarrays. ACS Chem. Biol. 12, 435–443 (2017). · DOI
  13. Van Meter, E. N., Onyango, J. A. & Teske, K. A. A review of currently identified small molecule modulators of microRNA function. Eur. J. Med. Chem. 188, 112008 (2020). · DOI
  14. Velagapudi, S. P. et al. Design of a small molecule against an oncogenic noncoding RNA. Proc. Natl Acad. Sci. USA 113, 5898–5903 (2016). · DOI
  15. Salta, E. & De Strooper, B. microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer’s disease. FASEB J. 31, 424–433 (2017). · DOI · Paper page
  16. Pichler, S. et al. The miRNome of Alzheimer’s disease: consistent downregulation of the miR-132/212 cluster. Neurobiol. Aging 50, 167 e161–167.e110 (2017). · DOI · Paper page
  17. Cha, D. J. et al. miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer’s patients. Front. Neurosci. 13, 1208 (2019). · DOI · Paper page
  18. Lau, P. et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol. Med. 5, 1613–1634 (2013). · DOI · Paper page
  19. Wong, H. K. et al. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease. Hum. Mol. Genet. 22, 3077–3092 (2013). · DOI · Paper page
  20. Hernandez-Rapp, J. et al. microRNA-132/212 deficiency enhances Abeta production and senile plaque deposition in Alzheimer’s disease triple transgenic mice. Sci. Rep. 6, 30953 (2016). · DOI
  21. Salta, E., Sierksma, A., Vanden Eynden, E. & De Strooper, B. miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Mol. Med. 8, 1005–1018 (2016). · DOI · Paper page
  22. Smith, P. Y. et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum. Mol. Genet. 24, 6721–6735 (2015). · DOI · Paper page
  23. Wang, Y. et al. Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer’s disease. Neurobiol. Aging 51, 156–166 (2017). · DOI · Paper page
  24. El Fatimy, R. et al. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 136, 537–555 (2018). · DOI · Paper page
  25. Walgrave, H. et al. Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease. Cell Stem Cell 28, 1805–1821.e1808 (2021). · DOI · Paper page
  26. Vo, N. et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl Acad. Sci. USA 102, 16426–16431 (2005). · DOI · Paper page
  27. van Zonneveld, A. J. et al. MicroRNA-132 regulates salt-dependent steady-state renin levels in mice. Commun. Biol. 3, 238 (2020). · DOI
  28. Barberan-Soler, S. et al. Decreasing miRNA sequencing bias using a single adapter and circularization approach. Genome Biol. 19, 105 (2018). · DOI
  29. Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom. Bioinform. 2, lqaa078 (2020). · DOI · Paper page
  30. Zhang, C. et al. Lnc00462717 regulates the permeability of the blood-brain tumor barrier through interaction with PTBP1 to inhibit the miR-186-5p/Occludin signaling pathway. FASEB J. 34, 9941–9958 (2020). · DOI
  31. Wolfle, U. et al. Salicin from Willow Bark can modulate neurite outgrowth in human neuroblastoma SH-SY5Y cells. Phytother Res. 29, 1494–1500 (2015). · DOI
  32. Park, J. H. et al., Neuroprotective effects of salicin in a gerbil model of transient forebrain ischemia by attenuating oxidative stress and activating PI3K/Akt/GSK3beta Pathway. Antioxidants 10, 629 (2021). · DOI
  33. Tanabe, N., Kuboyama, T., Kazuma, K., Konno, K. & Tohda, C. The extract of roots of sophora flavescens enhances the recovery of motor function by axonal growth in mice with a spinal cord injury. Front. Pharmacol. 6, 326 (2015).
  34. Tanabe, N., Kuboyama, T. & Tohda, C. Matrine promotes neural circuit remodeling to regulate motor function in a mouse model of chronic spinal cord injury. Neural Regen Res. 14, 1961–1967 (2019). · DOI
  35. Absalon, S. et al. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J. Neurosci. 33, 14645 (2023). · DOI · Paper page
  36. Lehmann, S. M. et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15, 827–835 (2012). · DOI · Paper page
  37. Khan, H. et al. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 14, 277–287 (2009). · DOI
  38. Magill, S. T. et al. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc. Natl Acad. Sci. USA 107, 20382–20387 (2010). · DOI · Paper page
  39. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002). · DOI · Paper page
  40. Brines, M. L., Dare, A. O. & de Lanerolle, N. C. The cardiac glycoside ouabain potentiates excitotoxic injury of adult neurons in rat hippocampus. Neurosci. Lett. 191, 145–148 (1995). · DOI
  41. Sun, Y., Dong, Z., Khodabakhsh, H., Chatterjee, S. & Guo, S. Zebrafish chemical screening reveals the impairment of dopaminergic neuronal survival by cardiac glycosides. PLoS One 7, e35645 (2012). · DOI
  42. Silva, M. C. et al. Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nat. Commun. 11, 3258 (2020). · DOI · Paper page
  43. Silva, M. C. et al. Discovery and optimization of tau targeted protein degraders enabled by patient induced pluripotent stem cells-derived neuronal models of tauopathy. Front. Cell Neurosci. 16, 801179 (2022). · DOI
  44. Silva, M. C. et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife 8, e45457 (2019). · DOI · Paper page
  45. Silva, M. C. et al. Human iPSC-derived neuronal model of tau-A152T frontotemporal dementia reveals tau-mediated mechanisms of neuronal vulnerability. Stem Cell Reports 7, 325–340 (2016). · DOI · Paper page
  46. Ni, D. et al. Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander. J. Exp. Ther. Oncol. 2, 278–285 (2002). · DOI
  47. Dunn, D. E. et al. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models. J. Neurochem. 119, 805–814 (2011). · DOI
  48. Van Kanegan, M. J. et al. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. J. Neurosci. 34, 963–968 (2014). · DOI
  49. Pastuzyn, E. D. et al. The neuronal gene arc encodes a repurposed retrotransposon gag protein that mediates intercellular RNA transfer. Cell 172, 275–288.e218 (2018). · DOI · Paper page
  50. Ashley, J. et al. Retrovirus-like gag protein Arc1 binds RNA and traffics across synaptic boutons. Cell 172, 262–274.e211 (2018). · DOI · Paper page
  51. Aruga, J. & Mikoshiba, K. Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. Mol. Cell Neurosci. 24, 117–129 (2003). · DOI
  52. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017). · DOI · Paper page
  53. Readhead, B. et al. Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nat. Commun. 9, 4412 (2018). · DOI
  54. Norkin, M., Ordonez-Moran, P. & Huelsken, J. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer. Cell Rep. 35, 109026 (2021). · DOI
  55. Liu, X. et al. ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade. Nat. Commun. 14, 4066 (2023). · DOI
  56. Reyes Gaido, O. E. et al. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci. Transl. Med. 15, eabq7839 (2023). · DOI
  57. Majd, H. et al. Deriving Schwann cells from hPSCs enables disease modeling and drug discovery for diabetic peripheral neuropathy. Cell Stem Cell 30, 632–647.e610 (2023). · DOI
  58. Currie, G. M. et al. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc. Med. J. 5, 130–135 (2011). · DOI
  59. Wang, J. K. T. et al. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl Acad. Sci. USA 103, 10461–10466 (2006). · DOI
  60. Dvela-Levitt, M., Ami, H. C., Rosen, H., Shohami, E. & Lichtstein, D. Ouabain improves functional recovery following traumatic brain injury. J. Neurotrauma 31, 1942–1947 (2014). · DOI
  61. Kinoshita, P. F. et al. Signaling function of Na,K-ATPase induced by ouabain against LPS as an inflammation model in hippocampus. J. Neuroinflammation 11, 218 (2014). · DOI
  62. Song, H. L., Demirev, A. V., Kim, N. Y., Kim, D. H. & Yoon, S. Y. Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer’s disease. Mol. Cell Neurosci. 95, 13–24 (2019). · DOI
  63. Mann, C. N. et al. Astrocytic alpha2-Na(+)/K(+) ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Sci. Transl. Med. 14, eabm4107 (2022). · DOI
  64. Laudisio, A. et al. Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey. Drugs Aging 26, 103–112 (2009). · DOI
  65. Johansson, S. et al. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 12, 475–483 (2001). · DOI
  66. Paula, S., Tabet, M. R. & Ball, W. J. Jr Interactions between cardiac glycosides and sodium/potassium-ATPase: three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of the enzyme versus activity inhibition. Biochemistry 44, 498–510 (2005). · DOI
  67. Hong, D. S. et al. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-kappaBeta and p70s6k, in patients with advanced solid tumors. Invest. New Drugs 32, 1204–1212 (2014). · DOI
  68. Benarroch, E. E. Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. Neurology 76, 287–293 (2011). · DOI
  69. Hansen, K. F. et al. miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct. Funct. 218, 817–831 (2013). · DOI · Paper page
  70. Schlingmann, K. P. et al. Germline de novo mutations in ATP1A1 cause renal hypomagnesemia, refractory seizures, and intellectual disability. Am. J. Hum. Genet. 103, 808–816 (2018). · DOI
  71. Dohrn, M. F. et al. De novo ATP1A1 variants in an early-onset complex neurodevelopmental syndrome. Neurology 98, 440–445 (2022). · DOI
  72. Vezyroglou, A. et al. The phenotypic continuum of ATP1A3-related disorders. Neurology 99, e1511–e1526 (2022). · DOI
  73. Stoilov, P., Lin, C. H., Damoiseaux, R., Nikolic, J. & Black, D. L. A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc. Natl Acad. Sci. USA 105, 11218–11223 (2008). · DOI
  74. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009). · DOI · Paper page

Cited by

Sorted by citations

See all 50

Metadata

Authors
Nguyen, L. D., Wei, Z., Silva, M. C., Barberán-Soler, S., Zhang, J., Rabinovsky, R., Muratore, C. R., Stricker, J. M. S., Hortman, C., Young-Pearse, T. L., Haggarty, S. J., & Krichevsky, A. M.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2023-11-21
Volume
14
Issue
1
ISSN
2041-1723
DOI
10.1038/s41467-023-43293-0
PMC
PMC10663445
Cited by
50
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review